Adicet Bio (ACET) vs Fractyl Health (GUTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Adicet Bio (ACET) has outperformed Fractyl Health (GUTS) over the past year, losing 61.4% versus a loss of 74.8%. Fractyl Health is the larger company by market cap ($56.1 million vs $53.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACET | GUTS |
|---|---|---|
| Share price | $5.74 | $4.23 |
| Market cap | $53.73M | $56.11M |
| 1-day change | -7.12% | -6.42% |
| YTD return | -31.83% | -83.98% |
| 1-year return | -61.38% | -74.82% |
| 5-year return | -95.54% | — |
| EPS (TTM) | $-10.42 | $-10.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.44 | $29.34 |
| 52-week low | $5.55 | $4.14 |
| Distance from 52-week high | -67.09% | -85.58% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +506.79% | +1327.90% |
| Average volume | 172.38K | 152.04K |
| Shares outstanding | 9.36M | 13.26M |
| Employees | 102 | 100 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACET has outperformed GUTS by 13.4 percentage points over the past year.
About Adicet Bio
ACET stock →Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
Healthcare · Biotechnology · 102 employees
About Fractyl Health
GUTS stock →Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Healthcare · Biotechnology · 100 employees
ACET vs GUTS FAQ
Which is bigger, Adicet Bio or Fractyl Health?
Fractyl Health (GUTS) is larger, with a market capitalization of $56.11M compared with $53.73M for Adicet Bio (ACET).
Which stock has performed better over the past year, ACET or GUTS?
ACET returned -61.38% over the past 12 months, compared with -74.82% for GUTS (price return, excluding dividends). Past performance does not predict future results.
Are Adicet Bio and Fractyl Health in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.